Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : JMAR Technologies(JMAR) -- Ignore unavailable to you. Want to Upgrade?

To: timwa who wrote (7958)	5/13/1999 6:48:00 PM
From: Bilberry	Read Replies (1) \| Respond to of 9695

Nothing wrong with venting Tim. I vent offline. As you pointed out by the survey, it appears that JMAR is aggressively going after the high yield businesses and sacrificing the short-term. I welcome this change. I would rather see JMAR get the x-ray to market 6 months earlier and sacrifice near term earnings rather than seeing a couple pennies per quarter which will do no great shakes to the stock price anyway. Since a lot of companies operate at losses and sell at tremendous market caps (INFX,etc.) based on their technology potential, I think this is the way to go. That is assuming that you believe that the x-ray sources are the way to go and that their market is truly in the billions.... From the way shareholders voted, JMAR is doing what they voted for. --Bilberry

To: timwa who wrote (7958)	5/13/1999 7:46:00 PM
From: Bilberry	Respond to of 9695

I just re-read the earnings release. Some very positive aspects to it. First the Long-term debt of JMAR was about halved according to the balance sheet figures, sales were up as well. Martinez said that revenues for 1999 will only be "slightly" downgraded. We should find out what that means in more precise terms. He talked a lot about the businesses and seemed to be very upbeat about Semiconductor and these proprietary chips, and of course very upbeat about the x-ray project. ''Overall, the outlook for JMAR remains very positive in all our operating areas,'' Dr. Martinez emphasized. JMAR Research continues to make major strides in adapting our X-ray and Britelight(TM)technologies to a range of high-potential market needs. Revenues increased 56% to $6,695,465 from $4,300,079 in the same period a year ago.